• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2021 Aug 26;27(11).
doi: 10.3201/eid2711.210636. Online ahead of print.
Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal

Luísa Canto E Castro, Ana Helena Guia Pereira, Rita Ribeiro, Catarina Alves, Luís Veloso, Vera Vicente, Dalila Alves, Inês Domingues, Cláudia Silva, Andreia Gomes, Marta Serrano, Ângela Afonso, Marc Veldhoen, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano de Sousa, Maria M Mota, Bruno Silva-Santos, Ruy M Ribeiro

Abstract

In September 2020, we tested 13,398 persons in Portugal for antibodies against severe acute respiratory syndrome coronavirus 2 by using a quota sample stratified by age and population density. We found a seroprevalence of 2.2%, 3-4 times larger than the official number of cases at the end of the first wave of the pandemic.

Keywords: COVID-19; Portugal; SARS-CoV-2; antibodies; coronavirus disease; coronaviruses; pandemic; population prevalence; respiratory infections; seroepidemiology; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom